Literature DB >> 16493480

Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA).

Manfred Rieger1, Silvia Ferrari, Johanna A Kremer Hovinga, Christian Konetschny, Andrea Herzog, Letizia Koller, Alfred Weber, Giuseppe Remuzzi, Michael Dockal, Barbara Plaimauer, Friedrich Scheiflinger.   

Abstract

We have established a new, enzyme-linked immunosorbent assay (ELISA) for the detection of ADAMTS13 antigen using purified polyclonal rabbit anti-human ADAMTS13 IgG. Normal plasma ADAMTS13 antigen levels span a concentration of 740-1420 ng/ml (median 1080 ng/ml) resulting in an ADAMTS13 activity to antigen ratio of 0.48 to 1.68 U/mug. In a cohort of HUS patients, ADAMTS13 antigen was in the normal range, whereas in hereditary TTP patients antigen levels were low to undetectable, in concordance with severe deficient ADAMTS13 activity. Plasma of acquired TTP patients was found to contain free as well as autoantibody-bound ADAMTS13. We also present evidence for circulating anti-ADAMTS13 antibody/ADAMTS13 antigen immune complexes not only in acutely ill or actively treated patients but also in patients who have already achieved clinical remission. This new developed ADAMTS13 antigen ELISA assay allows rapid determination of ADAMTS13 antigen levels in human plasma but is of limited predictive value for the diagnosis or treatment of acquired TTP due to the detection of ADAMTS13 in antibody complexes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493480     DOI: 10.1160/TH05-08-0550

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  23 in total

Review 1.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

2.  In vivo imaging analysis of the interaction between unusually large von Willebrand factor multimers and platelets on the surface of vascular wall.

Authors:  Miroslaw Rybaltowski; Yuko Suzuki; Hideo Mogami; Iwona Chlebinska; Tomasz Brzoska; Aki Tanaka; Fumiaki Banno; Toshiyuki Miyata; Tetsumei Urano
Journal:  Pflugers Arch       Date:  2011-04-15       Impact factor: 3.657

3.  Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger
Journal:  Haematologica       Date:  2013-11-15       Impact factor: 9.941

4.  ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.

Authors:  Shangbin Yang; Ming Jin; Shili Lin; Spero Cataland; Haifeng Wu
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

5.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 6.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

7.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.

Authors:  Eric M Ostertag; Khalil Bdeir; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; Lenka Yunk; Vincent M Hayes; David G Motto; Mortimer Poncz; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

8.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

9.  Thrombospondin 1 requires von Willebrand factor to modulate arterial thrombosis in mice.

Authors:  Prem Prakash; Paresh P Kulkarni; Anil K Chauhan
Journal:  Blood       Date:  2014-10-24       Impact factor: 22.113

10.  Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain.

Authors:  Wouter Pos; Nicoletta Sorvillo; Rob Fijnheer; Hendrik B Feys; Paul H P Kaijen; Gestur Vidarsson; Jan Voorberg
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.